News |  Contact |  Sitemap |  Disclaimer | 
news
About us  |   Business Development  |   Territories  |   Partners  |  
Ewopharma strengthens its oncology business
22.06.2017

Eisai Co. Ltd and Ewopharma AG have signed an agreement with which Ewopharma acquires the rights to commercialise several of Eisai's products in eleven countries in Central and Eastern Europe as of April 1st 2017.


Ewopharma will commercialise the breast cancer chemotherapy Halaven® (eribulin mesylate) in nine countries within the European Union (EU) (Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovenia) and in two countries outside of the EU (Bosnia & Herzegovina and Serbia). In addition the orphan drug Targretin® (bexarotene) to treat skin manifestations of advanced stage cutaneous T-cell lymphoma will be commercialized in Hungary and Poland. Furthermore Ewopharma will sell the epilepsy treatment Zonegran® (zonisamide) in Hungary.


For the full press release please click here.